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Abstract
Background: Surgical management of suspected LGG remains controversial. A key factor when deciding a surgical strategy
is often the tumors’ perceived relationship to eloquent brain regions
Objective: To study the association between tumor location, survival and long-term health related quality of life (HRQL) in
patients with supratentorial low-grade gliomas (LGG).
Methods: Adults ($18 years) operated due to newly diagnosed LGG from 1998 through 2009 included from two Norwegian
university hospitals. After review of initial histopathology, 153 adults with supratentorial WHO grade II LGG were included in
the study. Tumors’ anatomical location and the relationship to eloquent regions were graded. Survival analysis was adjusted
for known prognostic factors and the initial surgical procedure (biopsy or resection). In long-term survivors, HRQL was
assessed with disease specific questionnaires (EORTC QLQ-C30 and BN20) as well as a generic questionnaire (EuroQol 5D).
Results: There was a significant association between eloquence and survival (log-rank, p,0.001). The estimated 5-year
survival was 77% in non-eloquent tumors, 71% in intermediate located tumors and 54% in eloquent tumors. In the adjusted
analysis the hazard ratio of increasing eloquence was 1.5 (95% CI 1.1–2.0, p = 0.022). There were no differences in HRQL
between patients with eloquent and non-eloquent tumors. The most frequent self-reported symptoms were related to
fatigue, cognition, and future uncertainty.
Conclusion: Eloquently located LGGs are associated with impaired survival compared to non-eloquently located LGG, but in
long-term survivors HRQL is similar. Although causal inference from observational data should be done with caution, the
findings illuminate the delicate balance in surgical decision making in LGGs, and add support to the probable survival
benefits of aggressive surgical strategies, perhaps also in eloquent locations.
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Introduction
The clinical course for patients with diffuse infiltrating low-
grade gliomas (LGG) is often unpredictable. In such WHO grade
II gliomas, negative prognostic factors for survival are advanced
age, large tumor size, midline involvement, the presence of
neurologic deficits and astrocytoma histopathology [1]. In long
term survivors, health related quality of life (HRQL) is often
reduced, even in patients with stable disease [2].
Surgical management of suspected LGG is controversial [3–7].
A key factor when deciding on the surgical strategy is often the
tumors’ perceived relationship to so-called eloquent brain regions,
meaning involvement of sensorimotor regions, language cortices,
basal ganglia and/or larger white matter tracts. LGGs located
within or in close proximity to these areas may be subject to a less
aggressive surgical strategy to avoid acquired motor or verbal
deficits, while hopefully preserving patients’ HRQL [7]. As radical
resections are less often achieved in such regions, eloquence is
perhaps also a negative prognostic factor with respect to survival
[8]. Despite the key importance for clinical decision making, the
association between lesion eloquence for survival and long-term
HRQL has not been much explored in LGGs.
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In a consecutive population based series of patients with
supratentorial LGG treated at two centers we aimed to study if
eloquence in tumor location has implications for survival or quality
of life. Our secondary aim was to provide long-term data on
HRQL in LGG patients.
Methods
Ethics Statement
The study protocol was approved by the Regional Ethical
Committee for Health Region Mid-Norway. The need for
informed consent from participants in the retrospective part of
the study was waived by the Committee. All patients included in
the quality of life analyses have given their written and informed
consent.
Patient Selection
Patients were included from two university hospitals in Norway
(University Hospital of Northern Norway and St.Olavs University
Hospital). Adult patients, 18 years or older with histological
verified supratentorial LGG diagnosed in the 12-year period from
1998 through 2009 were screened for inclusion. These patients
were retrospectively identified from the pathology databases of the
respective hospitals. Only patients with supratentorial grade II
glioma (diffuse astrocytomas, oligodendrogliomas and oligoastro-
cytomas) were included in the study. The tumors were classified
according to the WHO classification system. [9] A neuropathol-
ogist from each hospital reviewed all LGG diagnosed at the other
hospital. In total, 169 cases were reviewed. The neuropathologists
were blinded for previous diagnosis, baseline characteristics, image
data and clinical outcomes. Initial diagnoses and review diagnoses
were discordant with respect to concluding with grade II glioma in
46 (27%) of cases. The neuropathologists were given case-numbers
with discordant results for a final consensus meeting where
consensus was obtained by evaluation of the slides in a multi-
headed microscope.
Clinical Characteristics and Treatment
Patient and treatment characteristics were based on retrospec-
tive review of medical records. We used the system suggested by
Sawaya et al when grading lesions with respect to anatomical
eloquence [10]. In the 11 patients (7%) where preoperative images
were unavailable for review we used subsequent images or the
radiology reports for grading eloquence. Still, in 4 patients (2%)
a highly reliable grading was not achieved and these patients were
excluded from the analyses involving eloquence. In the cases
where preoperative images couldn’t be evaluated we imputed the
tumor diameter using the mean tumor diameter from the treating
department. To adjust for important prognostic factors in LGG we
used the Pignatti score (age $40 years, diameter $6 cm, crossing
midline, deficit present and astrocytoma histology) [1]. Medical
important co-morbidity was scored with Charlson Co-morbidity
Index (CCI) [11]. No patients were excluded based on
radiographic findings or clinical status.
Surgical resections were carried out with use of the StealthH
neuronaviagion system (Medtronic, Minnesota, US) with or
without 2D ultrasonography at University Hospital of Northern
Norway. At St.Olavs University Hospital the SonoWandH
neuronavigation system (SonoWand, Trondheim, NO) with
integrated 3D-ultrasonsography was used with incorporation of
functional data (functional MRI and/or diffusion tensor imaging)
in selected eloquent lesions. Cortical mapping or awake surgery
was not utilized in any patients. Adjuvant therapy was usually
administered with surgically untreated tumors or with progressive
disease or signs of malignant transformation.
Follow-up
All patients were followed until death or until April 11th 2011.
The national population registry (Statistics Norway) provided the
patients’ current status (dead/alive) as of 11th April 2011 and the
date of death. No patients were lost to follow-up for survival
analysis. Patients who were still alive were contacted by mail with
a request to participate in the HRQL part of the study and to
answer HRQL questionnaires. Non-responders received one
remainder by mail.
Health-related Quality of Life
EORTC QLQ-C30. QLQ-C30 consist of cancer specific
functional and symptom scales in addition to a scale on overall
health and HRQL [12]. The questionnaire also contains single-
items, but none were explored in this study. Possible answers range
from 1–4, where 1 is described as ‘‘not at all’’, 2 as ‘‘a little’’, 3 as
‘‘quite a bit’’, and 4 as ‘‘very much’’. This applies for all but two
questions on global health status where the scale range from 1–7.
All domains are convertible to a score (0–100). A high score
represents a high HRQL and level of functioning and in the
symptom scales a higher score indicates more symptoms. We
assessed the overall HRQL, cognitive function and fatigue only.
The other items and domains in the questionnaire were not
explored.
EORTC QLQ-BN20. This questionnaire is specifically de-
signed for brain cancer patients [13]. The QLQ-BN20 consists of
four multi-item scales (domains): future uncertainty, visual
disorder, motor dysfunction, and communication deficit. Scores
in the domains are converted to a scale (0–100) where higher score
represents worse HRQL. We assessed all four domains. The
questionnaire also consists of seven single items in which none
were explored in this study.
The EuroQol 5D. EQ-5D is a generic and preference-
weighted measure of health-related quality of life [14]. The
questionnaire has been applied to a wide range of health
conditions and treatments. The EQ-5D has also been validated
in a Norwegian population [15]. The EQ-5D questionnaire is
a generic HRQL instrument. In EQ-5D five dimensions of HRQL
are scored: mobility, self-care, usual activities, pain/discomfort
and anxiety/depression with 3 possible answers to each dimension.
This results in the 243 different possible health states which are
transformed into an index value based on a large survey in the UK
population [16]. EQ-5D index value is from –0.594 to 1, where 1
corresponds to perfect health, and 0 to death. Negative values are
considered to be worse than death. A visual analogue scale where
patients rate their current health state on a line ranging from 0–
100 (worst to best imaginable health) forms the second part of the
EuroQol questionnaire. In this study only the index value was
assessed.
Statistics
All analyses were done with PASW, version 18.0. Central
tendencies are presented as means 6 SD. Independent samples t-
test was used for comparisons of means between groups. Survival
analysis assessing eloquent location was analyzed with log-rank test
and presented with Kaplan-Meier curves. The estimated 5-year
survival rates were created using life tables. In addition we created
a Cox multivariable model adjusting for the Pignatti score. For the
specific questions in the EORTC questionnaires we dichotomized
the items (‘not at all’ and ‘a little’ against ‘quite a bit’ and ‘very
much’) within the domains for descriptive analyses. Among
Outcomes in Eloquent LGG
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possible HRQL subscales we explored only the domains commu-
nication, motor function, visual function, future uncertainty and
cognitive function as well as more global categories (fatigue and
global HRQL). Statistical significance level was set to p#0.05. All
tests are two-sided.
Results
After the central review of initial histopathology in all LGG, 153
adults with supratentorial LGG were identified and included in the
study (figure 1). In 46 patients (31%) the tumor was located in an
eloquent area. Among the 46 patients with LGG in eloquent
locations, 22 (48%) underwent biopsy only as the initial surgical
procedure, as compared to 17 (29%) in non-eloquent lesions.
Baseline characteristics for the different groups are shown in
table 1.
Survival
Treatment and disease characteristics are demonstrated in
table 2. There was 8 patients (13%) among the 62 diseased who
did not receive any adjuvant therapy during the course of the
disease (terminal condition 4, early death 2 (22 days and 33 days),
refused therapy 1, unrelated cause of death with stable disease 1).
The main reason for not receiving adjuvant therapy among the 91
patients still being alive at end of follow-up was stable disease in 33
patients (36%). As shown in figure 2, there was a significant
association between eloquence and survival (log-rank, p,0.001).
The estimated 5-year survival was 77% (95% CI 65–89) in non-
eloquent tumors, 71% (95% CI 57–85) in intermediate located
tumors and 54% (95% CI 38–70) in eloquent tumors. Median
survival was 116 months for the entire group (95% CI could not be
calculated from the material). Median survival in patients with
eloquent lesions was 5.3 years (95% CI 3.0–7.5) while it was not
reached for the other groups. In the Cox multivariable model we
included the Pignatti score to adjust for important (and skewed, see
table 1) baseline parameters in addition to location (non-eloquent,
intermediate, eloquent). In this adjusted analysis a significant
survival difference was still seen with a relative hazard ratio of 1.5
(95% CI 1.1–2.0, p = 0.022) with closer distance to eloquent areas.
The Pignatti score proved its predictive capabilities in the same
analysis (p,0.001, hazard ratio 1.7, 95% CI 1.3–2.1).
Long-term Quality of Life
As of April 11th 2011 91 patients (59%) were still alive. There
were 36 (40%) non-responders. The non-responders had higher
Pignatti scores (p = 0.001) and Charlson Co-morbidity Index
(p = 0.007), but presented with seizures preoperatively as often as
responders (p = 0.359). Among living patients, 55 (60%) were
willing to participate in the HRQL study and returned the
questionnaires. Their baseline characteristics are presented in
table 1. In 30 (65%) patients the location of tumor was non-
eloquent, in 12 (22%) intermediate and in 12 (22%) eloquent. The
mean follow-up among questionnaire responders was 7.2 years
(range 1.6–13.2). The long-term HRQL data from the 55 LGG
survivors is presented in table 3.
Brain Tumor and Cancer Specific Quality of Life
A descriptive analysis of patients with high symptom burden
within the HRQL domains that were explored in this study are
presented in figure 3. The fatigue domain was most often affected
as 44% experienced symptoms in at least one of the fatigue related
questions. Other frequent complaints were memory loss (36%)
followed by tiredness (35%), rest requirement (33%) and un-
certainty concerning the future (29%). As only one patient had
a high symptom burden with respect to seizure activity, seizures
were not included it in the analyses. The internal consistency
measured with Cronbach’s alpha was between 0.80–0.94 for all
domains except ‘‘visual disorder’’ with 0.60, and as a consequence
it was excluded from between group comparisons.
Eloquence and Long-term Quality of Life
We analyzed functions and overall HRQL in patients with non-
eloquent lesions compared to patients with lesions in intermediate
and eloquent locations (table 3). For categories in the BN20
module the differences between groups were not significant for any
of the explored items (communication deficit, motor dysfunction,
and future uncertainty). There were also no statistical significant
differences in cognitive function, fatigue, overall HRQL, and EQ-
5D index value.
Discussion
In the present study, we found impaired survival in patients with
LGGs in eloquent locations compared to patients with tumors in
other areas. The impact of eloquence on survival remained after
adjusting for established prognostic factors that were skewed at
baseline. In long-term survivors, reported HRQL was not
statistically different in patients with eloquent and non-eloquent
lesions.
In our study of 153 consecutive patients, 30% of all LGGs were
defined as eloquent in location based on the Sawaya classification
system [10]. However, to be remembered, eloquence as defined
anatomically [10] does not always correlate to functional regions
as characterized with various techniques, such as functional MRI
Figure 1. Flow-chart describing patient selection.
doi:10.1371/journal.pone.0051450.g001
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or direct cortical stimulation. It was for example recently reported
that presumed eloquence from imaging can be a modifiable risk
factor for impaired survival since eloquent LGG can still be safely
removed in many instances [8]. Perceived eloquence is still often of
key importance when neurosurgeons decide on the surgical
strategy with respect to aggressiveness and invasiveness of the
procedure in addition to planning of which techniques or
technology to utilize. This was demonstrated in our study by the
declining percentage of resections with increasing eloquence of the
tumor. However, is eloquence as important for the patients as it is
for the surgeons? Neurosurgeons have tradition for a special
respect for areas perceived of so-called eloquence with a traditional
focus on the executive motor and language regions, even though
there are presumably no non-functional regions in the brain.
Much less attention and respect is given to brain regions that may
affect various cognitive functions, personality functions or sensory
neglect. Is the discrimination against other brain functions
justified? In unselected patients with gliomas we earlier observed
that new neurologic deficits have an immense effect on short-term
HRQL [17]. Although a paresis may perhaps seem more
important than the mild cognitive deficit in the short term, this
may be different in the long term. How different surgically induced
deficits affect HRQL over time is largely unknown, and how the
response shift that may occur over time affects results remains
speculative [18]. In a recent cross-sectional study of long term
HRQL in LGGs, Aaronson et al found that most of the
impairment in HRQL was attributed to the cancer diagnose per
se, but with an additional burden in cases with neurocognitive
symptoms and poor seizure control. While motor deficits were
rare, approximately one quarter of patients reported serious
problems with neurocognitive functioning, particularly memory
and concentration [2]. This is supported by the findings in our
Table 1. Baseline characteristics.
Baseline Non-eloquent (N=59) Intermediate (N=44)
Eloquent
(N=46) With HRQL{ (N=55)
Age 6 SD 42615 43614 48617 41613
Age $40 years 29 (49%) 23 (52%) 29 (63%) 26 (47%)
Female 29 (49%) 19 (43%) 15 (33%) 25 (45%)
Preoperative KPS $80 54 (92%) 35 (80%) 31 (67%) 50 (91%)
Charlson co-morbidity index, mean 6 SD 0.1260.38 0.2560.53 0.2260.66 0.1360.34
Treatment year, mean 6 SD 200363 200463 200464 200463
Maximal tumor diameter, mm 6 SD 39614 50615 64619 43616
Tumor diameter $60 mm 4 (7%) 12 (27%) 27 (59%) 8 (15%)
Midline or bilateral involvement 1 (2%) 8 (18%) 12 (26%) 1 (2%)
Preoperative contrast enhancement 7 (12%) 9 (21%) 11 (24%) 6 (11%)
Pignatti score
0 6 (10%) 2 (5%) – 7 (13%)
1 26 (44%) 11 (25%) 13 (28%) 25 (45%)
2 23 (39%) 16 (36%) 9 (20%) 17 (31%)
3 3 (5%) 11 (25%) 13 (28%) 5 (9%)
4 1 (2%) 4 (9%) 6 (13%) 1 (2%)
5 – – 5 (11%) –
Initial surgical procedure
Biopsy 17 (29%) 19 (43%) 22 (48%) 10 (18%)
Resection 42 (71%) 25 (57%) 24 (52%) 45 (82%)
Histopathology
Astrocytoma 44 (75%) 35 (80%) 35 (76%) 29 (53%)
Oligodendroglioma 9 (15%) 6 (14%) 6 (13%) 16 (29%)
Oligoastrocytoma 6 (10%) 3 (7%) 5 (11%) 10 (18%)
Initial symptoms1
Seizure 40 (68%) 33 (75%) 30 (65%) 33 (60%)
Seizure only 38 (64%) 26 (59%) 26 (57%) 31 (56%)
Headache 13 (22%) 13 (30%) 12 (26%) 12 (22%)
Motor 2 (4%) 4 (9%) 7 (15%) 1 (2%)
Cognitive 4 (7%) 7 (16%) 11 (24%) 8 (15%)
Dysphasia 1 (2%) – 2 (4%) 1 (2%)
Asymptomatic 2 (4%) 1 (2%) 1 (2%) 2 (4%)
*KPS = Karnofsky Performance Status "Eloquent graded as defined by Sawaya. [10] 1Several symptoms may be registered per patient. {HRQL = Health-related quality of
life. There were four missing values with respect to grading of eloquence.
doi:10.1371/journal.pone.0051450.t001
Outcomes in Eloquent LGG
PLOS ONE | www.plosone.org 4 December 2012 | Volume 7 | Issue 12 | e51450
study with a relatively high symptom burden in several assessed
HRQL domains, especially for cancer related symptoms and less
pronounced in specific brain symptoms including functions
associated with eloquent location. Except from seizures, that are
known to lower HRQL, [2] the disease specific symptom burden
was largely similar to previous studies using the EORTC QLQ-
BN20 questionnaire (table 4). However, concerning future un-
certainty somewhat lower scores were noted in the LGG studies at
long-term follow-up compared to high-grade gliomas recently
diagnosed. If this reflects the difference in aggressiveness of the
disease or the time since diagnose or both remain unknown.
Seizures and use of antiepileptic drugs are well-known risk-factors
for impaired HRQL and cognition [19–22]. It seems like ongoing
seizure activity is related to impaired HRQL, while use of
antiepileptic drugs have a stronger association with cognitive
function [22]. In fact, the study from Klein et al suggest that
patients with stable disease with grade II glioma and seizures have
similar HRQL to epilepsy patients without glioma [22]. However,
as only one patient had high symptom burden with respect to
seizures in the present study, the impact or seizures were not
explored in the HRQL analyses.
Several important aspects when caring for patients with LGG
were illuminated in our study. First, eloquence affects the chosen
surgical strategy and seems to have an independent and dose-
response effect on survival. A direct biological effect of tumor
location on survival cannot be out-ruled, but the finding may also
be attributed to the prognostic importance of extensive resections
[23]. Thus, more widespread use of technology to aid safe and
Figure 2. Association between eloquence and survival (N=149). A decreased survival was seen with closer distance of tumor to sensitive
regions as demonstrated with the Kaplan-Meier curve (p,0.001, log-rank test). The estimated 5-year survival was 77% (95% CI 65–89) in non-
eloquent tumors, 71% (95% CI 57–85) in intermediate located tumors and 54% (95% CI 38–70) in eloquent tumors.
doi:10.1371/journal.pone.0051450.g002
Table 2. Treatment and disease characteristics after initial surgery.
Non-eloquent (N=59)
Intermediate
(N=44) Eloquent (N=46) With HRQL{ (N=55)
Surgical complications 2 (4%) 4 (9%) 6 (13%) 4 (7%)
New or worsened neurological deficits* 9 (15%) 12 (27%) 8 (17%) 14 (26%)
Early (first 6 months) postoperative radiotherapy 16 (27%) 16 (36%) 21 (46%) 14 (26%)
Ever radiotherapy 30 (51%) 33 (75%) 35 (76%) 25 (46%)
Early (first 6 months) postoperative chemotherapy 7 (12%) 12 (27%) 12 (26%) 9 (16%)
Ever chemotherapy 21 (36%) 28 (64%) 28 (61%) 18 (33%)
Later/repeated resection 15 (25%) 18 (41%) 15 (33%) 12 (22%)
Malignant transformation1 18 (31%) 24 (55%) 25 (54%) 10 (18%)
*Documented neurological deterioration of any magnitude in the postoperative course. 1Malignant transformation if verified new contrast enhancement or malignant
histology from new biopsy or resection. {HRQL = Health-related quality of life. There were four missing values with respect to grading of eloquence.
doi:10.1371/journal.pone.0051450.t002
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Table 3. Eloquence in relation to quality of life scores.
Non-eloquent* (N=30) Eloquent* (N=24) p-value
BN20: Communication deficit 17 21 0.481
BN20: Motor dysfunction 18 23 0.422
BN20: Future uncertainty 21 23 0.721
QLQ-C30: Fatigue 31 33 0.850
QLQ-C30: Cognitive function 68 69 0.957
QLQ-C30: Overall quality of life 72 74 0.837
EQ-5D: Index value 0.76 0.74 0.785
*Non-eloquent is here grade 1 defined by Sawaya [10], while eloquent here denotes grade 2 and 3 (intermediate and eloquent). This grouping was done to achieve
adequate number of patients in each group. There was one missing value with respect to tumor location.
doi:10.1371/journal.pone.0051450.t003
Figure 3. Specific symptoms within domains (N=55). Percentage in domains represents patients with one or more symptom within category.
Only patients with ‘‘quite a bit’’ and ‘‘very much’’ symptoms are presented.
doi:10.1371/journal.pone.0051450.g003
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extensive resections in eloquent lesions is perhaps beneficial.
Second, our findings may indicate that our surgeons have been
careful enough to avoid overly aggressive treatment since
neurological deterioration was infrequent in eloquent locations
and since HRQL was much alike in the two groups. More
aggressive resections in eloquent locations could perhaps have
been favorable with respect to survival, but how long-term HRQL
could have been affected by more radical surgery remains
speculative. This demonstrates the typical dilemma patients and
their treating neurosurgeons regularly have to deal with in glioma
surgery. Third, functions in eloquent brain regions may perhaps
be of less importance for patients HRQL than perceived by
surgeons. Unfortunately, a study with high-quality data on
longitudinal HRQL in consecutive LGG patients is still lacking.
In sum, our study may suggest that a surgical strategy advocating
extensive resections may outweigh the risks in most LGG. With
the use of modern technology such as 3D ultrasound, intraopera-
tive MRI [24], or mapping techniques [25] quite safe resections
are most often possible, even in eloquent locations. Further
refinement of tools and techniques should be encouraged to safely
enhance tumor removal.
The major strengths of this study is the high external validity
due to the unselected population based inclusion, the review of
histopathology for the survival analysis and the adjusted survival
analysis with respect to known prognostic factors. Without this
adjustment the worse prognosis seen in eloquent tumors could
simply have been explained by patients having worse functional
status and larger tumors more often crossing the midline. In
addition, the long-term HRQL data is rare in the LGG literature
and offer a more holistic perspective on the tolls of the disease and
its management than the traditional surgical outcome measures
such as extent of resection or complication rates. However, this
study has limitations as well. Unfortunately we have no in-
formation on resection grades since early MRI was not routinely
performed at both hospitals. Collection of data except for HRQL
was done retrospectively. However, survival is a robust end-point
unaffected by the collection of data. Further, the responding
patients who provided HRQL data were pre-selected by their
survivorship – and those responding seemed to in the best
prognostic group at time of diagnose. Thus, the long-term findings
in this study may best apply to patients with good prognostic
factors at presentation. Perhaps also influencing the results was the
rather low statistical power in the HRQL analyses.
Conclusion
In conclusion, patients diagnosed with supratentorial WHO
grade II glioma in eloquent brain regions are less likely to undergo
resections and have impaired survival compared to patients with
tumors in other regions. There was no apparent association
between HRQL and lesion eloquence in long-term survivors.
Making causal inference from observational may be treacherous,
still our findings illuminate the delicate balance in surgical decision
making in LGGs, and add support to the probable survival
benefits of aggressive surgical strategies, perhaps also in eloquent
locations.
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